Drug evaluation: CNTO-1275, a mAb against IL-12/IL-23p40 for the potential treatment of inflammatory diseases.
Centocor Inc is developing CNTO-1275 (ustekinumab), a subcantaneous mAb against the p40 subunit of IL-12 and IL-23, for the potential treatment of inflammatory diseases such as psoriasis, psoriatic arthritis, multiple sclerosis (MS) and Crohn's disease (CD). In July 2004, a phase II trial for MS had commenced, and by July ... 2006 this study was no longer recruiting patients. By May 2005, CNTO-1275 was in phase II studies for CD, and by January 2006 the antibody was in phase III studies for psoriasis. In December 2005, a phase II trial in patients with psoriatic arthritis had commenced and had finished recruiting by January 2007.
Mesh Terms:
Animals, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Autoimmune Diseases, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Drug Evaluation, Preclinical, Humans, Interleukin-12 Subunit p40
Animals, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Autoimmune Diseases, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Drug Evaluation, Preclinical, Humans, Interleukin-12 Subunit p40
Curr Opin Investig Drugs
Date: Nov. 01, 2007
PubMed ID: 17979029
View in: Pubmed Google Scholar
Download Curated Data For This Publication
182059
Switch View:
- Chemical Interactions 2